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Abstract
Background: The prognosis for malignant gliomas remains dismal. We addressed the safety,
feasibility and preliminary clinical activity of the vaccinations using autologous glioma cells and
interleukin (IL)-4 gene transfected fibroblasts.
Methods: In University of Pittsburgh Cancer Institute (UPCI) protocol 95-033, adult participants
with recurrent glioblastoma multiforme (GBM) or anaplastic astrocytoma (AA) received gross total
resection (GTR) of the recurrent tumors, followed by two vaccinations with autologous fibroblasts
retrovirally transfected with TFG-IL4-Neo-TK vector admixed with irradiated autologous glioma
cells. In UPCI 99-111, adult participants with newly diagnosed GBM or AA, following GTR and
radiation therapy, received two intradermal vaccinations with the TFG-IL4-Neo-TK-transfected
fibroblasts admixed with type-1 dendritic cells (DC) loaded with autologous tumor lysate. The
participants were evaluated for occurrence of adverse events, immune response, and clinical
response by radiological imaging.
Results and Discussion: In UPCI 95-033, only 2 of 6 participants received the vaccinations. Four
other participants were withdrawn from the trial because of tumor progression prior to
Published: 19 December 2007
Journal of Translational Medicine 2007, 5:67 doi:10.1186/1479-5876-5-67
Received: 15 October 2007
Accepted: 19 December 2007
This article is available from: http://www.translational-medicine.com/content/5/1/67
© 2007 Okada et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 10
(page number not for citation purposes)
Journal of Translational Medicine 2007, 5:67 http://www.translational-medicine.com/content/5/1/67production of the cellular vaccine. However, both participants who received two vaccinations
demonstrated encouraging immunological and clinical responses. Biopsies from the local vaccine
sites from one participant displayed IL-4 dose-dependent infiltration of CD4+ as well as CD8+ T
cells. Interferon (IFN)-γ Enzyme-Linked Immuno-SPOT (ELISPOT) assay in another human
leukocyte antigen (HLA)-A2+ participant demonstrated systemic T-cell responses against an HLA-
A2-restricted glioma-associated antigen (GAA) epitope EphA2883–891. Moreover, both participants
demonstrated clinical and radiological improvement with no evidence of allergic encephalitis,
although both participants eventually succumbed with the tumor recurrence. In 99-111, 5 of 6
enrolled participants received scheduled vaccinations with no incidence of major adverse events.
Monocyte-derived DCs produced high levels of IL-12 p70. Treatment was well tolerated; however,
we were unable to observe detectable IFN-γ post-vaccine responses or prolonged progression-
free survival in these participants.
Conclusion: Feasibility challenges inherent in the generation of a patient-specific gene
transfection-based vaccine strongly suggests the need for more practical formulations that would
allow for the timely administration of vaccines. Nevertheless, successful generation of type-1 DCs
and preliminary safety in the current study provide a strong rationale for further efforts to develop
novel glioma vaccines.
Background
Although cellular mechanisms underlying the "immuno-
logically privileged" status of the brain and brain tumors
have been increasingly well-characterized during the past
decade [1], it has also become apparent that this privi-
leged status is not absolute. Immunotherapy may develop
as an effective and safe treatment modality for malignant
gliomas, a disease that continues to have a poor prognosis
[reviewed in [2]].
Previous studies indicate that active immunization with
tumor cells genetically engineered to express cytokines
may positively influence the outcome of an anti-tumor
immune response [3,4], and this hypothesis is supported
by clinical responses of patients with melanoma [5].
With regard to vaccine strategies against CNS gliomas, we
have compared various cytokines and delivery modes to
find the most efficacious strategy of cytokine gene therapy
against intracranial (IC) tumors in the rat 9L gliosarcoma
model [6,7]. In these preclinical studies, we observed that
peripheral immunization with IL-4 transfected rat 9L cells
achieved the most potent therapeutic benefit [7]. To gain
additional mechanistic insight into the efficacy of this
approach, we evaluated the effects of transgene-derived
IL-4 on endogenous cytokines, such as IL-12 and inter-
feron (IFN)-γ [8]. These type-1 cytokines were necessary
for long-lasting protective memory response against the
tumor, and local paracrine production of IL-4 in vaccine
sites promoted the accumulation and maturation of IL-
12-secreting tumor-infiltrating DCs, which were capable
of inducing tumor-specific CTL responses. These results
suggest that vaccines consisting of tumor cells engineered
to produce the type-2 cytokine IL-4 critically depend on
type-1 immunity for their observed therapeutic efficacy.
Indeed, IL-4 plays an important role in DC maturation [9]
and promotes IL-12 secretion from DCs [10-12].
With regard to the vector design to deliver IL-4, to enhance
the safety of gene-transfected vaccines, we incorporated
the Herpes Simplex Virus-Thymidine Kinase (HSV-TK)
downstream of IL-4 in our retroviral vector construct
(TFG-hIL4-Neo-TK) [13]. Vaccination was effective in ani-
mals that received gancyclovir (GCV) treatment to elimi-
nate live tumor cells persisting after the local host
immune response to the vaccine [6].
On the basis of these observations, we developed a phase
I clinical trial of vaccination with autologous tumor cells
and autologous fibroblasts that are transfected with the
TFG-hIL4-Neo-TK to evaluate feasibility, safety, local and
systemic immunological response, as well as preliminary
therapeutic activity of the approach in patients with recur-
rent malignant glioma (UPCI95-033) [14]. As IL-4 pro-
motes maturation and IL-12 production of DCs, we
subsequently developed another trial for patients with
newly diagnosed malignant glioma, using TFG-hIL4-Neo-
TK-transfected fibroblasts and type-1-promoting DCs [15]
loaded with autologous glioma lysate (UPCI 99-111)
[16]. In both trials, generation of sufficient gene-trans-
fected fibroblasts required at least 7 to 8 weeks, which
posed a major feasibility issue, especially in patients with
recurrent malignant glioma. Nevertheless, successful gen-
eration of type-1 DCs and preliminary safety in the cur-
rent study provide a strong rationale for further efforts to
develop novel glioma vaccines.Page 2 of 10
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Patients
Eligible patients were at least 18 years of age with histo-
logically confirmed primary (UPCI 99-111) or recurrent
(UPCI 95-033) supratentorial GBM or AA. Other eligibil-
ity criteria included the following: 1) Tumors had to be
suitably located for subtotal resection; 2) resected tumor
cells must be viable and sterile; 3) Karnofsky performance
status ≥ 60% prior to surgery and prior to receiving the
vaccine; 4) no evidence of systemic infection; 5) negative
HIV test and negative hepatitis B surface antigen test prior
to the first vaccination; 6) patients had to be off corticos-
teroids for at least two weeks prior to, and during the vac-
cine treatment; and 7) adequate liver, hematopoetic and
renal function (WBC > 2000 cells/mm3, platelet > 50,000
cells/mm3, bilirubin < 2 mg/dl, creatinine < 2 mg/dl).
Written informed consent was obtained for publication
from the patients and/or their relatives.
Obtaining autologous glioma cells and fibroblasts for 
vaccines
Methods and procedures for processing autologous gli-
oma cells and fibroblasts were detailed previously
[14,16,17]. In brief, for glioma cells, the UPCI Tissue Bank
obtained surgical specimens directly from the operating
room after a surgical pathologist had reviewed the tissue
to ensure adequate diagnostic material had been
obtained, and released the remainder to the Tissue Bank
personnel. Tumor cells were recovered from Ficoll-
Hypaque gradients and washed in tissue culture medium.
Dissociation of glioma tissues was conducted under sterile
conditions in a laminar flow hood by a certified Tissue
Bank technician. After mechanical dissociation and wash-
ing, tissue fragments were digested with 0.14% colla-
genase Type I (200 units per mg; Sigma C/0130) and 0.1%
DNAse Type I (500 Kunitz units per ml; Sigma D/0876) at
37°C for 30 to 45 minutes. Then, free cells were decanted
through three layers of sterile medium wet nylon mesh
(163T; Martin Supply Company, Baltimore, MD) into a
50 ml centrifuge tube. After washing, cells were pooled
and counted, and the cell viability assessed by the Trypan
blue exclusion test.
Skin harvest for establishing fibroblast cultures was
obtained from each patient by either excision of a portion
of the skin (approximately 3 cm by 6 cm) from the torso
at time of craniotomy (95-033) or punch-excision (7 mm
in diameter) from the torso under local anesthesia (99-
111). The skin grafts were minced using a surgical scalpel
into 1–2 mm2 pieces, which were then cultured in T25
plastic culture flasks with culture medium supplemented
with 10% human AB serum, 5 µg/ml basic fibroblast
growth factor and antibiotics, and were allowed to attach
to the plastic (30–60 min) at 37°C in an atmosphere of
5% C02 in air. Then, the flasks were incubated undis-
turbed for 5 to 7 days. When the fibroblasts had expanded
sufficiently, they were briefly (up to 10 min) incubated
with 0.25% trypsin in EDTA (Gibco, culture grade) at
37°C, and then detached cells were washed and trans-
ferred to a fresh flask in culture medium.
Transfection and growth of fibroblasts
Retroviral vector supernatant from a ψCRIP/TFG-hIL4-
neo-TK producer cell line master cell bank was prepared in
the Human Gene Therapy Applications Laboratory
(HGTAL) within the University of Pittsburgh [13]. The
safety criteria requirements of the supernatant and master
cell bank have been previously reported [14,16].
Although we had planned, if possible, to transfect patient-
derived glioma cells in UPCI 95-033, these cells were not
successfully transfected with the clinical grade vector
supernatant. Therefore, we used fibroblasts transfected
with TFG-hIL-4-neo-TK admixed with irradiated glioma
cells in UPCI 95-033. UPCI 99-111 was designed to use
autologous fibroblasts transfected with TFG-hIL-4-neo-
TK, which were admixed with tumor lysate-loaded DCs
for the final vaccine formulation. Cultured fibroblasts
were transfected as soon as significant growth was
observed according to our previously described methods
[13,14,16]. Twenty-four hours after transfection, these
cells were then exposed to the selective pressure of 0.3 mg/
ml of G418 to facilitate isolation of transfected cells.
Generation of lysate-loaded DCs
For generation of type-1 DCs in UPCI 99-111, partici-
pants' whole blood was obtained by conventional periph-
eral blood draw (up to 100 ml/draw). Peripheral blood
mononuclear cells (PBMC) were isolated by Ficoll-Paque
PLUS (Pharmacia, Piscataway. NJ), and were plated onto
plastic flasks (10–15 × 106 PBMC/T-25 flask) and incu-
bated in 37°C and 5% CO2 for 45 minutes. Plastic-adher-
ent monocytes were cultured in Iscove's-modified
Dulbecco's medium containing 10% fetal bovine serum
(Certified US origin, Gibco), 250 IU/ml recombinant
human (rh) IL-4 and 500 IU/ml rh granulocyte macro-
phage-colony stimulating factor (GM-CSF) (FDA-
approved reagents) for 6 days. Cryopreserved glioma cells
were thawed, and then lysed by 5 cycles of freeze and thaw
in PBS. After centrifugation, the lysate was obtained as the
supernatant, then added to the DC culture, together with
the mixture of maturation-inducing and type-1 polarizing
cytokines (1000 U/ml IFN-γ, 20 ng/ml IL-1β and 50 ng/ml
TNF-α). One T-25 flask of cells not given this cytokine
mixture served as a control in assessing the IL-12 produc-
tion capability of type-1 polarized vs. standard DCs. At 16
hours after the addition of tumor lysate, the cells were
washed and prepared for vaccination. On the vaccination
day, a small aliquot of DCs (8 × 104) were tested for IL-12
production capability by specific ELISA.Page 3 of 10
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It required 7 to 8 weeks to generate sufficient (at least 2 ×
107) transfected fibroblasts for each participant. In UPCI
95-033, participants were to receive the first vaccination as
soon as this quantity of vaccine cells became available.
However, 4 of 6 participants had tumor re-recurrence
before the transfected cells proliferated sufficiently, forc-
ing their withdrawal from the study. For both of the par-
ticipants who received the vaccine in UPCI 95-033, five
different formulations were prepared for primary immu-
nization on day 1 by establishing 3 log dilutions of trans-
fected fibroblasts, with the most potent vaccine
containing up to 107 transfected fibroblasts elaborating
up to 103 ng/IL-4/48 hours and admixed with 5 × 106 irra-
diated glioma cells. The total number of fibroblasts in
each preparation to achieve a given cytokine production
level was adjusted by adding non-transfected fibroblasts.
Five sites for immunization were oriented vertically and
positioned 2 cm apart in the mid-inguinal line over the
patient's left thigh. At two weeks after the initial vaccina-
tion (on day 15), the 5 immunization sites were punch
biopsied and evaluated to determine the dose of IL-4 asso-
ciated with the most intense mononuclear cell infiltrate.
This immunization procedure was repeated on day 15. At
this time, 5 immunization sites were placed over the right
thigh. Each preparation consisted of as many as 107 trans-
fected fibroblasts to provide the maximum dose of IL-4
that was found to be free of significant toxicity in primary
immunization. Each patient was treated with GCV
(Cytovene, Roche Laboratories, Inc., Nutley, NJ; 5 mg/kg
× 2/day) from days 8 to 14 and 22 to 28 to ensure elimi-
nation of gene-transfected fibroblasts.
In UPCI 99-111, following GTR of the primary tumor,
each participant received fractionated external beam radi-
ation therapy (FEBRT; 2 Gy/dose × 30 doses), while gene-
transfected autologous fibroblasts were prepared. Follow-
ing the completion of FEBRT, and as soon as generation of
sufficient (at least 2 × 107) transfected fibroblasts was con-
firmed, DCs for the first vaccine were cultured from
peripheral blood-derived monocytes. The first DC vaccine
was administered along with IL-4 transfected fibroblasts
on day 7 after the peripheral blood draw. On day 7 after
the first vaccine, preparation of the second DC vaccine
was initiated with fresh peripheral blood-derived mono-
cytes, and thus a course of vaccines was consisted of two
intradermal vaccinations with a two week interval (on
days 1 and 15), provided that the patient had not suffered
a severe local reaction such as abscess or ulceration. Each
vaccine formulation was composed of 1 × 106 lysate-
loaded DCs and irradiated (8,000 rads) fibroblasts pro-
ducing 2 × 103 ng IL-4/48 h. On the day of each vaccina-
tion, before vaccination, the final vaccine formulation was
confirmed for the status of sterility, as assessed by absence
of gram stain evidence of bacteria, mycoplasma and endo-
toxin.
Assessment of safety
Our definitions of toxicity were according to Common
Toxicity Criteria Version 3.0 (CTC, v3.0). Regimen-Limit-
ing Toxicity (RLT) was defined as ≥ Grade 2 hypersensitiv-
ity reaction and any Grade 3 or greater adverse events with
the following exceptions; chills, malaise, fatigue and fever.
Because tumor progression was expected in the majority
of patients on this protocol, this was not considered a tox-
icity per se. Similarly, new seizures or changes in seizure
frequency were carefully evaluated to determine whether
they were related to the study treatment, or to disease pro-
gression. If Grade 3 or greater toxicity of any sort, not
attributable to disease progression, was detected in >1 of
3 patients or > 2 of 6, then further accrual to the study was
to be halted.
Immunological endpoints
In UPCI 95-033, local immune response was monitored
by immunohistochemistry of tissue samples from the vac-
cine sites [14]. For evaluation of systemic immune
response, enzyme linked immuno-spot assay (ELISPOT)
assays were performed using PBMC samples collected on
days 1 (pre-vaccine), 8, 15 (prior to second vaccine) 22,
30 ± 1 and 60 ± 1. To optimize the sensitivity of the assays,
PBMC were re-stimulated in vitro for 5 days with low-dose
(approx. 50 U/ml) IL-2 and autologous DCs loaded with
lysate. Frequencies of IFN-γ producing spots reacting
against DC loaded with glioma-lysate were measured as
the indicators of type-1 T-cell immune response. For a par-
ticipant with HLA-A2 haplotype (the second participant
in UPCI 95-033), frequencies of IFN-γ producing spots
were measured against human glioma-associated, HLA-
A2-restricted CTL epitopes IL-13 receptor α2 (IL-
13Rα2)345–353 [18] and EphA2883–891 [19] pulsed onto
transporter associated with antigen processing-deficient,
HLA-A2+ T2 cells. A participant was considered to have
responded, if at each of two consecutive time points, the
number of spots was double that at baseline, and there
were at least 25 spots/50,000 CD8+ cells.
Objective clinical response in radiographic analyses
Patients were assessed at one month following their initial
vaccination and every two months thereafter for evidence
of tumor response using physical examination or radio-
graphic studies. Responses were defined as follows:
A. Complete response – disappearance of all measurable
disease for at least 1 month without the development of
new lesions.
B. Partial response – 50% or greater decrease in the sum of
the radiologically calculated tumor volume of all measur-Page 4 of 10
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size of existing lesions or appearance of new lesions.
C Minor response – 25–50% decrease in the sum of the
radiographically calculated tumor volume of all measura-
ble lesions lasting at least 4 weeks with no increase in the
size of existing lesions or appearance of new lesions.
D. Stable disease – no change or < 25% change in the sum
of the radiologically calculated tumor volume of all meas-
urable lesions lasting at least 4 weeks with no increase in
the size of existing lesions or appearance of new lesions.
E. Progressive disease – any patient manifesting a > 25%
increase in the radiologically calculated tumor volume of
all measurable lesions or exhibiting the development of
new lesions.
Results
Treatment of enrolled patients
In UPCI 95-033, only 2 of 6 enrolled participants received
scheduled two vaccinations; 4 other participants were
withdrawn from the trial because of tumor progression
prior to the first vaccination, as it required at least 7 to 8
weeks to generate sufficient numbers of IL-4-transfected
vaccine cells (Table 1). Although the trial was initially
designed to accrue a total 10 participants, we terminated
accrual in this trial after 6 eligible participants because of
this major feasibility issue.
In UPCI 99-111, 5 of 6 enrolled patients received the
scheduled two vaccinations (Table 1). The participant
who did not receive the vaccines presented with a rapid
tumor recurrence immediately after FEBRT. It was decided
to terminate accrual in this trial due to: 1) the lack of sys-
temic immunological or clinical responses in 5 treated
patients with this regimen; and 2) the dose of DC and
number of vaccinations in this study were thought to be
suboptimal based on other studies demonstrating encour-
aging clinical activity of DC-based glioma vaccines [20-
22]. This issue is also considered a feasibility issue in the
study design.
Toxicity
No participants experienced regimen-limiting toxicity and
there were no deaths on these studies. In UPCI 95-033,
grade 2 and 1 skin reactions were seen at the vaccine injec-
tion sites in the first and the second participants receiving
the vaccines, respectively. In UPCI 99-111, 1 of 5 partici-
pants receiving the vaccines reported one transient epi-
sode of grade 1 headache that was possibly associated
with treatment. There were no other adverse events that
were possibly, probably or definitely associated with treat-
ment.
Production of IL-12 from autologous DCs
One innovative aspect of UPCI 99-111 trial was that it
employed type-1 polarizing DCs [15]. In 5 patients who
received vaccines, we evaluated IL-12 p70 production in
response to CD40L stimulation using CD40L-transfected
J558 cells (Figure 1). In Case 1, only standard DCs were
generated because the protocol was amended after case 1
to employ use of type-1, rather than standard DCs. Type-
1 DCs were generated for Cases 3 to 6, and produced high
levels of IL-12 p70, ranging 20–116 ng/1 × 106 cells/24
hrs, whereas control standard DCs from the same donors
produced only background levels (less than 2 ng/1 × 106
cells/24 hrs) of IL-12 p70. These results demonstrate that
Table 1: Patient profiles
95-033
Case # Age Gender Tumor # of previous recurrence Vaccine/Adverse events
1 63 Male Lt. Temporal GBM 2 Yes/Grade 2 skin reaction
2 60 Male Lt. Temporal AA 3 Yes/Grade 1 skin reaction
3 40 Male Rt. Frontal GBM 3 No due to tumor progression
4 57 Male Lt. Parieto/Occi GBM 1 No due to tumor progression
5 32 Female Lt. Parieto/Occi GBM 1 No due to tumor progression
6 53 Female Rt. Frontal GBM 2 No due to tumor progression
99-111
Case # Age Gender Tumor TTP (Months) Vaccine/Adverse events
1 56 Male Lt. Parietal GBM 4 Yes/Grade 1 headache
2 66 Male Rt. Frontal GBM N/A No due to tumor progression
3 45 Male Lt. Temporal GBM 10 Yes/None
4 53 Male Lt. Occipital GBM 6 Yes/None
5 50 Male Rt. Frontal GBM 6 Yes/None
6 61 Female Rt. Temporal GBM 4 Yes/None
TTP: Time To ProgressionPage 5 of 10
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successfully generated in the current trial.
Immunological response
In UPCI 95-033, two participants who received vaccina-
tions against their recurrent GBM demonstrated local (the
first patient) or systemic (the second patient) immuno-
logical responses. Biopsies from the vaccine sites of the
first patient displayed IL-4 dose-dependent infiltration of
CD4+ and CD8+ T cells [23]. Although ELISPOT assays did
not demonstrate a systemic immune response against
autologous glioma cells in this patient, the second vaccine
recipient in this trial was HLA-A2-positive, allowing us to
evaluate the induction of systemic T-cell responses against
the HLA-A2-restricted GAA epitopes EphA2883–891 [19]
and IL-13Rα2345–353 [18] using ELISPOT assays. In this
patient, vaccinations using autologous glioma as the anti-
gen source induced a specific IFN-γ response against
EphA2883–891 that was sustained for at least 6 weeks post-
vaccination (Figure 2), although a specific response
against IL-13Rα2345–353or autologous bulk glioma cells
was not detectable in the same assays. No PBMC samples
were collected at any later time points, and thus we were
unable to monitor the persistence of such responses for
longer periods of time. Immunohistochemical analysis of
the vaccine site biopsy sample, which was performed in
the first patient [23], was not performed for the second
patient due to suboptimal sample quality.
In 99-111, we were unable to detect increased IFN-γ
responses in any of 5 patients who received the scheduled
two vaccines.
Clinical response
In UPCI 95-033, despite the fact that only of two patients
completed the protocol-defined sequence of vaccinations,
these two patients, both of whom had recurrent GBM,
demonstrated radiological improvement during the 4
months after vaccination [[23] and (Figure 3)]. However,
both patients eventually succumbed to tumor recurrence,
which started at 6 months following the first vaccination.
In UPCI 99-111, 5 patients received two vaccinations, and
time to progression was 4, 10, 6, 6 and 4 months, respec-
tively, after resection of newly diagnosed GBM (Table 1).
IL-4 gene transfected glioma cell vaccine elicited an IFN-γ respons ag inst EphA2 883–891 epitopeFigur  2
IL-4 gene transfected glioma cell vaccine elicited an 
IFN-γ response against EphA2 883–891 epitope. 
PBMC samples were obtained on days 1 (pre-vaccine on the 
day of the first vaccine), 8, 15 (on the day of the second vac-
cine), and 42, and saved as frozen cells until all these cells 
were thawed at the same time, cultured in the presence of 
20 IU/ml hIL-2 and autologous glioma cells for 5 days, and 
evaluated for the frequency of IFN-γ-producing cells in 
response to T2 cells loaded with the HLA-A2-binding 
EphA2883–891 peptide using ELISPOT assay. Each well con-
tained 5 × 104 CD8+ cells and each group was evaluated in 
triplicate. Specific IFN-γ spots were calculated by subtracting 
the average of control spots (triplicate variation within a 
group was less than 10% in non-peptide-loaded T2 cell 
groups) from the total numbers of spots in peptide-loaded 
groups. Values indicate averages of triplicate samples for 
each time point, and bars indicate standard deviations. The 
number of spots in each post-vaccine time point was at least 
three times the standard-deviation of the pre-vaccine value.
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We described our results from two gene therapy trials in
patients with recurrent or newly diagnosed malignant gli-
oma, UPCI 95-033 and 99-111, respectively. We identi-
fied common challenges in the administration of these
protocols. Both protocols utilized participants' autolo-
gous fibroblasts that had to be stably transfected with the
TFG-hIL4-Neo-TK retroviral vector, and expanded to suffi-
cient numbers. A retroviral vector was chosen because of
stable expression and positive efficacy data in preclinical
models [6,7]. However, these processes required at least 7
to 8 weeks, which posed a major feasibility concern. Espe-
cially in the UPCI 95-033 trial, 4 of 6 participants were
withdrawn from the study due to tumor re-recurrence
before they could receive the first vaccine. In addition, the
first patient who received the vaccines had a rapid recur-
rence after the surgery for tumor debulking and vaccine
cell harvesting, and underwent another tumor resection
before beginning vaccination [23]. Indeed, in the litera-
ture [24], the median time to further tumor progression
for patients with recurrent malignant glioma, even with
therapy, is only 8 weeks. We performed skin harvesting
during the craniotomy of recurred tumor for UPCI 95-
033. As craniotomy and debulking surgery are usually per-
formed as soon as these interventions are clinically indi-
cated, there are no practical ways to perform skin
harvesting and transfection earlier. In UPCI 99-111, this
issue was not as significant as in UPCI 95-033 as only one
of 6 participants was withdrawn due to tumor recurrence
before the first vaccine. In this trial, standard FEBRT,
which typically requires 6 weeks (2 Gy/dose × 30 doses),
was used following surgical resection of primary tumors,
and this may have temporarily suppressed tumor growth
and provided an adequate time for vaccine generation and
post-irradiation delivery.
The primary endpoint of these studies was evaluation of
safety, and we did not observe any regimen-limiting toxic-
ity. Because autologous whole glioma cells were used as
the source of the vaccines, there was a theoretical concern
for inducing autoimmune encephalitis. Although the lack
of autoimmune events in our two trials is reassuring in
this regard, it does not indicate the ultimate safety of such
approaches, and continued vigilance for such toxicity is
warranted, particularly because only 7 evaluable partici-
pants were accrued. It has been demonstrated that the
clinical benefit of immunotherapy in other types of can-
cers is often associated with induction of autoimmunity
[25]. On the other hand, patients with advanced cancers
and compromised immune systems may not be ideal can-
didates for assessing either the toxicity or efficacy of ther-
apeutic cancer vaccines [26]. Further evaluation of these
important issues is warranted in larger numbers of glioma
patients receiving current, more intensive, vaccine regi-
mens.
With regard to induction of immune response, two partic-
ipants in UPCI 95-033 who received vaccines composed
of IL-4-transfected fibroblasts and irradiated autologous
glioma cells demonstrated either local (i.e. immune cell
Regression of recurrent glioblastoma following vaccination with autologous glioma cells admixed with IL-4-transfected fibrob-lastsFigure 3
Regression of recurrent glioblastoma following vaccination with autologous glioma cells admixed with IL-4-
transfected fibroblasts. Axial gadolinium-enhanced T1-weighted MR images obtained from the 2nd participant in UPCI 95-
033. Enhanced lesions were measured independently by a neuroradiologist.
January 14,   February 19, April 21
1.6 x 2.2 cm 1.6 x 2.0 cm 0.8 x 1.3 cm
1.6 x 2.2 cm 1.6 x 2.0 cm 0.8 x 1.3 cm
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POT response against EphA2-derived epitope) immune
responses. These observations are consistent with previ-
ous clinical trials in our institute that local production of
IL-4 by gene-transfected fibroblasts at the vaccine site
caused local endothelial activation and recruitment of
immune effectors [27,28]. On the other hand, no evi-
dence of systemic immune response was observed in five
participants in UPCI 99-111 who received IL-4-transfected
fibroblasts admixed with DCs loaded with tumor-lysate.
These results were somewhat surprising because we had
expected that the vaccine formulation using type-1 DCs
would be more potent than the formulation in UPCI 95-
033. In UPCI 99-111, each participant received only two
intradermal injections of 1 × 106 lysate-loaded type-1
DCs. The dose of DC and number of vaccinations in this
study were probably suboptimal based on other studies
demonstrating encouraging clinical activity of DC-based
glioma vaccines [20-22]. In these studies, higher DC num-
bers and repeated vaccinations (1 × 107/injection × 3 or
more vaccinnations) were employed.
In addition to the intensity of vaccine regimens, careful
consideration is required for optimal administration
routes of DC vaccines. In a randomized study comparing
direct intra-lymph-nodal, intravenous and intradermal
administration of DC vaccines in patients with metastatic
melanomas [29], the intra-lymph-nodal route was well-
tolerated for up to 5 × 107 DCs/injection, and induced sig-
nificantly higher levels of specific CD8+ T cells based on
cytokine secretion, when compared with other routes. The
feasibility, safety and efficacy of intra-lymph-nodal
administration of DC-based vaccines has also been dem-
onstrated using the activation of antigen-specific CD4+ T
cell responses as an endpoint [30]. Therefore, in our cur-
rently ongoing type-1 DC-based trials (UPCI 04-136 and
05-115), we selected ultrasound-guided intra-lymph-
nodal injections of type-1 DCs.
Novel type-1 DCs were employed in UPCI 99-111, and
these DCs generated from each participant demonstrated
enhanced IL-12 p70 producing capability in vitro com-
pared to standard DCs from the same donors. These
results indicate that we have established standard opera-
tion procedures for GMP-grade type-1 DCs for our ongo-
ing and future type-1 DC-based trials. In addition, further
improvement of the DC culture protocol has lead to
development of a serum-free culture protocol for type-1
DCs [15]. Type-1 DCs are expected to induce type-1
immune effector cells, including T-helper (Th)1 and type-
1 cytotoxic T-lymphocytes (Tc1). Our recent studies in
murine brain tumor models have demonstrated that type-
1 T-cell response is particularly favorable for anti-brain
tumor immunotherapy owing to high level surface expres-
sion on Tc1 cells of a type-1 chemokine receptor CXCR3
[31] and an integrin, very late antigen-4 [32], both of
which mediate critical roles in efficient trafficking of anti-
tumor T-cells to the brain tumor site. Therefore, our ongo-
ing and future development of glioma vaccine-based
immunotherapy is directed towards induction of effective
and safe type-1 immunity in patients suffering from brain
tumors.
Although IL-4 is typically described as an inducer of a
type-2 immune response [33], local delivery of IL-4 at an
immunization site induced IL-12 production by antigen-
presenting cells, and Th1-type responses in our pre-clini-
cal tumor vaccine model [34] as well as in an infectious
disease (Leishmania major) model [35]. Interestingly, in
this Leishmania major model [35], systemic or prolonged
recombinant (r)IL-4 delivery rather induced Th2-
response, suggesting bi-functional roles of IL-4 depending
upon target cell types (i.e. antigen-presenting cells vs. T-
cells). Indeed, in vitro exposure of DCs to IL-4 promotes
IL-12 secretion from DCs [10-12].
We also evaluated preliminary therapeutic activity of these
regimens. In two participants in UPCI 95-033 who
received scheduled vaccines, temporary stabilization of
disease and radiological improvement was observed for 4
to 6 months. However, the clinical course of the first
patient after vaccination was complex due to transiently
increased gadolinium enhancement on MRI scans at 2 to
3 months after vaccination [23]. This transient worsening
may not have been true tumor progression, but pseudo-
tumor progression representing inflammatory response at
the tumor site. Biopsy of the tumor would have been the
ultimate modality to distinguish these two scenarios. As
we currently employ more intensified vaccine regimens
(discussed in the next paragraph), the distinction between
true- and pseudo-tumor progression is becoming a more
critical issue. Biopsy may not always be clinically justifia-
ble in patients with recurrent glioma. The utility of MR
spectroscopy and metabolic positron emission tomogra-
phy (PET) imaging for differentiating tumor progression
from immune-mediated inflammatory treatment effect
remains to be established. In 99-111, the median time to
progression after surgical resection in 5 participants who
received scheduled vaccines was 6 months (ranging 4 to
10 months); and this is not superior to the current stand-
ard regimen with FEBRT and temozolomide (6.9 months)
or FEBRT alone (5.0 months) [36]. The low intensity of
the vaccine regimen in the UPCI 99-111 study, with only
1 × 106 DC/injection × two injections, may have limited
the manifestation of any therapeutic immune response.
Future studies will need to determine whether intensifica-
tion of the vaccine approach can enhance therapeutic effi-
cacy without a counterbalancing induction of detrimental
autoimmunity.Page 8 of 10
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led us to understand the critical roles of type-1 immunity
for brain tumor immunotherapy, effective type-1 immu-
nity may also be achieved by clinically more feasible
modalities than IL-4 transfected fibroblasts. Indeed, our
recent preclinical study has demonstrated that a Toll-like
receptor-3 ligand poly-ICLC, which has been extensively
evaluated for safety in patients with glioma [37], enhances
type-1 anti-glioma immunity when combined with
peripheral vaccine regimens [38]. We have also isolated
and characterized HLA-A2-restricted CD8+ CTL epitopes
derived from human GAAs, such as IL-13Rα2 [18] and
EphA2 [19] to develop vaccines using "off the shelf" syn-
thetic peptides for these epitopes. Based on these studies,
we recently implemented vaccine trials evaluating safety
and immunological activity of type-1 inducing DCs
loaded with synthetic peptides encoding these GAA-
derived CTL epitopes in HLA-A2+ patients with recurrent
glioma (UPCI 04-136 and 05-115). In these trials, to date,
7 of 8 participants successfully received 4 scheduled vacci-
nations with 2-week intervals without tumor recurrence,
suggesting improved feasibility of these novel vaccine
approaches.
Our ongoing progress in basic understanding in brain
tumor immunology will allow us to develop more effi-
cient and feasible immunotherapy strategies for patients
suffering from these intractable diseases.
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